mgh brigham and astra zeneca and vaccine for cancer?
"Google Search
The collaboration between Mass General Brigham (MGH Brigham) and AstraZeneca is broad, focusing on accelerating clinical trials and developing digital health solutions, particularly in oncology.
While a dedicated, named "AstraZeneca-MGH Brigham cancer vaccine" program is not immediately identified as a single entity, the partnership heavily involves MGH Brigham in the execution of advanced cancer research, including trials for vaccines and immunotherapies.
Here is a breakdown of the partnership's focus and the nature of the cancer vaccines being investigated:
1. The MGH Brigham and AstraZeneca Partnership Focus
The primary focus of the collaboration is to use MGH Brigham's vast clinical infrastructure and data to streamline and accelerate clinical research, leveraging AstraZeneca's portfolio. Key areas include:
Clinical Trial Optimization: Using MGB's real-world data (genomics, imaging, patient records) and digital platforms (like Evinova) to quickly assess study feasibility, identify eligible patients, and improve overall trial efficiency.
Oncology and Chronic Disease: While the initial partnership was also focused on chronic diseases like heart failure and asthma, AstraZeneca is a major player in oncology, and MGH Brigham is one of the nation's leading cancer research centers, running over 1,000 active clinical trials.
2. The Designated Antigen Being Sought in Cancer Vaccines
The cancer vaccines currently being studied and developed by MGH Brigham researchers and their partners are therapeutic cancer vaccines, and the designated antigen being sought is highly personalized or tumor-specific.
Target Antigen: Neoantigens (Tumor-Specific Antigens)
Unlike traditional vaccines that target foreign pathogens, therapeutic cancer vaccines are designed to target proteins unique to a patient's tumor cells.
These unique proteins, called neoantigens, are generated by the tumor's specific genetic mutations.
Mechanism (Personalized mRNA Vaccines): Many cutting-edge cancer vaccine trials, including those conducted at MGH Brigham and its peers (often using technology developed by companies like Moderna or BioNTech in collaboration with large pharma), use mRNA technology.
Process: Researchers first sequence a patient's tumor (whole exome sequencing) to find its unique set of mutations/neoantigens.
Vaccine: An mRNA vaccine is then custom-designed for that patient, encoding instructions for the patient's body to produce those specific neoantigens. This trains the patient's immune system (T-cells) to recognize and attack any cell expressing those tumor-specific proteins.
In summary, the designated antigen in the type of cancer vaccine research MGH Brigham is heavily involved in is a personalized set of neoantigens specific to an individual patient's tumor."
Market Data 
Markets 
AI
